Risk of Getting COVID-19 in People With Multiple Sclerosis
A Case-Control Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 12, 2021
- Accepted in final form December 15, 2021
- First Published January 19, 2022.
Author Disclosures
- Pietro Iaffaldano, MD,
- Giuseppe Lucisano, MSc Stat,
- Alessia Manni, MD,
- Damiano Paolicelli, MD,
- Francesco Patti, MD,
- Marco Capobianco, MD,
- Vincenzo Brescia Morra, MD,
- Patrizia Sola, MD,
- Ilaria Pesci, MD,
- Giacomo Lus, MD,
- Giovanna De Luca, MD,
- Alessandra Lugaresi, MD,
- Paola Cavalla, MD,
- Sara Montepietra, MD,
- Giorgia Teresa Maniscalco, MD,
- Franco Granella, MD,
- Paolo Ragonese, MD,
- Marika Vianello, MD,
- Laura Brambilla, MD,
- Rocco Totaro, MD,
- Simona Toscano, MD,
- Simona Malucchi, MD,
- Maria Petracca, MD,
- Lucia Moiola, MD,
- Diana Ferraro, MD,
- Vito Lepore, MD,
- Paola Mosconi, Biol Sci D,
- Michela Ponzio, PhD,
- Gioacchino Tedeschi, MD,
- Giancarlo Comi, MD,
- Mario Alberto Battaglia, MD,
- Massimo Filippi, MD,
- Maria Pia Amato, MD and
- Maria Trojano, MD
- on behalf of the Italian MS Register
- Pietro Iaffaldano, MD,
Advisory board member for Biogen, Merck, Novartis, Genzyme.
NONE
Travel funding and speaker honoraria from Biogen, Novartis, Merck, Genzyme, Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giuseppe Lucisano, MSc Stat,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alessia Manni, MD,
NONE
NONE
1) Sanofi-Genzime, speaker honoraria 2) Roche, speaker honoraria and funding for travel to a conference
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Damiano Paolicelli, MD,
1) Sanofy- genzyme (2018); 2) Biogen (2018) ; 3>) Merck-Serono (2018)
NONE
NONE
NONE
NONE
NONE
NONE
Receive consulting fees from Merck Serono (2010-2018);Bayer Schering (2010); TEVA (2018); Sanofi genzyme (2018); Biogen (2018); Novartis (2018)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francesco Patti, MD,
I served as advisory board member in the following companies: Almirall, Bayer, Biogen, Bristol Meyers Squibb, Celgene, Merck, Novartis, Roche, Sanofi and TEVA I received unconditioned research grant by Biogen and Merck I received research grant by RELOAD Onlus Association, and FISM I received research grants by University of Catania
NONE
I received speaker honoraria from Almirall and Bayer in 2014, and 2015, and 2016, from Novartis in 2013, 2014 and 2015,2016 from TEVA in 2013, 2014 and 2015, 208, 2019 from Biogen in 2013, 2014 and 2015, 2016, 2017, 2019 and 2020 I received speaking honoraria from Roche in 2018 and 2019 and from Sanofi in 2017, 2018 and 2019
I serve BMC Neurology as Senior Editor; I serve Multiple Sclerosis Hindawi as associate editor; I serve Frontiers in Neurology as associate editor; I serve Neurology and Therapy as Associate editor
NONE
NONE
I received personal compensation from: Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi-Genzyme, TEVA
NONE
NONE
NONE
NONE
NONE
NONE
Grant from University of Catania (2007-2008-2009-2010- 2011, 2015, 2017, 2018, 2020)
Grant from FISM (2010, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020)
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Capobianco, MD,
Commercial entity: Biogen, Sanofi-Genzyme, Novartis, Bayer-Schering, TEVA, Almirall, Merck-Serono, Roche, Mylan, Bristol
NONE
Speaking honoraria from: Almirall, Biogen, Novartis, Sanofi-Genzyme, Roche, Merck-Serono, Teva, Beck Dickinson
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vincenzo Brescia Morra, MD,
Received grants for scientific advisory boards from Biogen, Roche and Sanofi-Genzyme
NONE
Received grants for travel and speaker honoraria from MerkSerono, Bayer, TEVA, Sanofi-Genzyme, Novartis, Biogen, Almirall
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrizia Sola, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ilaria Pesci, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giacomo Lus, MD,
NONE
NONE
speaker honoraria from Novartis,Sanofi-aventis travel honoraria from Novartis, Sanofi-Aventis, Bayer Schering Pharma, Biogen Idech
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giovanna De Luca, MD,
Served on Scientific Advisory Board for Merck Serono, Roche and Sanofy Genzyme
NONE
travel grants (Merck Serono, Biogen, Novartis, Sanofi Genzyme) Honoraria for speaking engagements (Roche, Merck Serono, Novartis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alessandra Lugaresi, MD,
(1) Biogen, (2) Bristol Myers Squibb, (3) Merck Serono, (4) Novartis, (5) Roche, (6) Sanofi- Genzyme, (7)Teva
NONE
(1)Biogen, travel and speaker honoraria, (2)Merck Serono, travel and speaker honoraria, (3) Novartis, travel and speaker honoraria, (4) Roche, travel and speaker honoraria, (5) Sanofi-Genzyme, travel and speaker honoraria, (6)Teva, travel and speaker honoraria
(1) BMC Neurology, associate editor, 2016-2021, (2) Multiple Sclerosis and Neuroimmunology (specialty section of Frontiers in Immunology and Frontiers in Neurology), Review Editor on the Editorial Board, 2021-present
NONE
NONE
NONE
(1)Biogen, (2)Merck Serono, (3) Novartis, (4) Roche, (5) Sanofi- Genzyme and (6)Teva
NONE
Fondazione Italiana Sclerosi Multipla, non profit observational and interventional studies MS-BASE foundation profit and non-profit observational studies
NONE
(1) Novartis (2) Sanofi-Genzyme
NONE
NONE
(1) AISM (Associazione Italiana Sclerosi Multipla),
NONE
NONE
NONE
NONE
NONE
NONE
- Paola Cavalla, MD,
(1) Merck-Serono (2) Sanofi-Genzyme (3) Roche (4) Biogen (5) Novartis
NONE
(1) Speaker honoraria from Sanofi-Genzyme, Teva, Biogen, Novartis, Merck- Serono, Roche, Cellgene-BMS. (2) Travel support for participation/ speaking to scientific meetings from Biogen, Sanofi-Genzyme, Novartis, Merck-Serono, Teva, Roche, Cellgene-BMS.
NONE
NONE
NONE
NONE
(1) Biogen (2) Sanofi-Genzyme (3) Merck-Serono (4) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sara Montepietra, MD,
advisory board merck and novartis and biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giorgia Teresa Maniscalco, MD,
NONE
NONE
(1) Biogen, funding for travel to conference (2) Teva, funding for speak al conference (3) Novartis, funding for travel to conference (4) Roche, funding for travel to conference (5) Merck, funding for speak al conference
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Franco Granella, MD,
(1)Biogen(2) Novartis (3) Sanofi Genzyme (4) Merck Serono (5) Roche
NONE
(1) Biogen (2) Novartis (3) Merck Serono (4)Sanofi Genzyme (5) Roche
(1) BMC Neurology, associate editor, since 2020 (2) Frontiers in Neurology, associate editor, 2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paolo Ragonese, MD,
NONE
NONE
Speaker onoraria or travel expenses for congress participation from: Almirall, Teva, Genzyme Sanofy, Merck, Biogen, Roche, Novartis, Bristoll-Myers.
International Journal Molecular Science BMC Neurology Frontiers in Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Almirall, Roche.
NONE
Managing Group of the Neuroepidemiology panel at the European Academy of Neurology since december 2021.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marika Vianello, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Brambilla, MD,
(1) Biogen (2) Sanofi-Genzyme (3) Merck-Serono
NONE
(1) Sanofi-Genzyme (2) Merck-Serono (3) Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Patient-Centered Outcomes Research Institute
NONE
NONE
NONE
NONE
NONE
NONE
- Rocco Totaro, MD,
NONE
NONE
speaker onoraria from Biogen, Merck-Serono, Novartis, Roche, Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simona Toscano, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simona Malucchi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Petracca, MD,
NONE
NONE
(1) HEALTH&LIFE S.r.l., speaking honoraria,
(1) Frontiers in Neurology, Guest Associate Editor in Applied Neuroimaging, 2020-2021,(2) Frontiers in Radiology, Review Editor in Neuroradiology,2021,(3) BMC Neurology, Editorial Board Member, 2021
NONE
NONE
NONE
(1) Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lucia Moiola, MD,
NONE
NONE
I received travel and speaker honoraria from Biogen, Merck Serono, Sanofi-Genzyme, Celgene, Novartis, Roche, Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Diana Ferraro, MD,
Advisory Board for Biogen, Merck and Roche
NONE
1)Merck Serono, travel and speaker honoraria 2)TEVA Pharmaceutical Industries, travel and speaker honoraria 3)Novartis, travel and speaker honoraria 4)Biogen Idec, travel and speaker honoraria 5)Sanofi-Genzyme, travel honoraria
BMC Neurology, Associate Editor since 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vito Lepore, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I work as a scientific consultant for a non-profit entity: Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paola Mosconi, Biol Sci D,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Mario Negri Institute IRCCS receives funds by FISM as a Technical Methodological Structure of the Italian MS and related disorders Register.
NONE
NONE
NONE
NONE
NONE
NONE
- Michela Ponzio, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gioacchino Tedeschi, MD,
I serve on the scientific advisory board for TEVA, Roche, Lilly, Allergan
NONE
I have received speaker honoraria from Sanofi-Aventis, Merck Serono, Bayer Schering Pharma, Novartis, Biogen- Dompe` AG; as weel as funding for travel from Bayer Schering Pharma, Biogen-Dompe` AG, Merck Serono, Novartis and Sanofi Aventis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giancarlo Comi, MD,
Received personal fees from Novartis,Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGgA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F.Hoffman-La Roche, Roche SpA, Almirall SpA and MedEx
NONE
Received personal fees from Novartis,Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGgA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F.Hoffman-La Roche, Roche SpA, Almirall SpA and MedEx
1) Neurological Sciences, associate editor, 2011-
NONE
NONE
NONE
Received personal fees from Novartis,Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGgA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F.Hoffman-La Roche, Roche SpA, Almirall SpA and MedEx
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mario Alberto Battaglia, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Filippi, MD,
NONE
NONE
Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries
Editor-in-Chief (2012-present), Journal of Neurology; Associate Editor, Neurological Sciences (2016-present); Associate Editor, Human Brain Mapping (since 2020) Associate Editor, Radiology (since 2015)
NONE
NONE
NONE
Almiral, Alexion, Biogen, Merck-Serono, Novartis, Roche, Sanofi
NONE
NONE
NONE
1) Commercial entity: Roche
1) Italian Ministry of Health; grant number: GR-2013- 02357415; role: co-investigator; duration: September 2016-December 2020 2) Italian Ministry of Health; grant number: RF-2018- 12366746; role: PI; duration: 15/06/2020 Â 14/06/2023
NONE
1) Fondazione Italiana Sclerosi Multipla (FISM) 2) ARiSLA (Fondazione Italiana di Ricerca per la SLA)
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Pia Amato, MD and
member of Advisory Boards for Biogen, Merck , Teva, Novartis, Sanofi Aventis, Genzyme, Celgene BMS and Roche
NONE
honoraria for speaking from Biogen, Merck , Novartis , Teva, Genzyme, Almirall and Sanofi Aventis, Celgene BMS and Roche
Editor for Multiple Sclerosis Journal Member of the Editorial board of Frontiers in Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Unrestricted research grants from Biogen , Merck , Bayer , Sanofi Aventis, Teva, Roche, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Trojano, MD
MT has served on scientific Advisory Boards for Biogen, Novartis, Merck, BMS Celgen, Roche and Genzyme
NONE
M.T. received honoraria for travel, consultancy or speaking from Biogen, Roche, Sanofi, Merck, Genzyme, and Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
M Trojano received research support for her Institution by Novartis, Biogen, Roche, and Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Basic Medical Sciences (P.I., G.L., A.M., D.P., M.T.), Neurosciences and Sense Organs, University of Bari Aldo Moro; CORESEARCH (G.L.), Pescara; Dipartimento di Scienze Mediche e Chirurgiche e Tecnologie Avanzate (F.P., S.T.), GF Ingrassia, Sez. Neuroscienze, Centro Sclerosi Multipla, Università di Catania; SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla (CRESM) (M.C., S.M.), AOU San Luigi—Orbassano (TO); Department of Neurosciences (V.B.M., M.P.), Reproductive and Odontostomatological Sciences, ‘Federico II’ University of Naples; Centro malattie Demielinizzanti (P.S.), Azienda Ospedaliera Universitaria di Modena/OCB, UO Neurologia; Centro SM UO Neurologia, Ospedale Di Vaio (I.P.), Fidenza, AUSL PR; Multiple Sclerosis Center (G. Lus), II Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples; Centro Sclerosi Multipla (G.D.L.), Clinica Neurologica, Policlinico SS. Annunziata, Chieti; IRCCS Istituto delle Scienze Neurologiche di Bologna (A.L.), UOSI Riabilitazione Sclerosi Multipla, Bologna; Dipartimento di Scienze Biomediche e Neuromotorie (A.L.), Università di Bologna; Centro SM (P.C.)—Neurologia 1 D.U.—AOU Citta' Della Salute E Della Scienza Di Torino; Centro SM (S.M.), S.O.C. Neurologia, Arcispedale Santa Maria Nuova, AUSL-IRCCS Reggio Emilia; Neurological Clinic and Multiple Sclerosis Center (G.T.M.), A Cardarelli Hospital, Naples; Centro Sclerosi Multipla (F.G.), Azienda Ospedaliero-Universitaria di Parma; Department of Biomedicine (P.R.), Neuroscience and Advanced Diagnostics, University of Palermo; Centro Sclerosi Multipla UO Neurologia—Ospedale (M.V.), Treviso; Fondazione IRCCS Istituto Neurologico “C. Besta” U.O. Neuroimmunologia e Malattie Neuromuscolari (L.B.); Centro Malattie Demielinizzanti (R.T.), Clinica Neurologica, Ospedale San Salvatore—L'Aquila; Dipartimento di Neurologia (L.M., M.F.), Neurofisiologia e Neuroriabilitazione, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; Department of Biomedical (D.F.), Metabolic and Neurosciences, University of Modena and Reggio Emilia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS (V.L., P.M.), Milano, Italy; Scientific Research Area (M.P.), Italian Multiple Sclerosis Foundation, Genoa; First Division of Neurology (G.T.), Department of Advanced Medical and Surgical Sciences, MRI Research Center SUN-FISM, AOU, University of Campania “Luigi Vanvitelli,” Naples; Institute of Experimental Neurology (G.C.), IRCCS San Raffaele Hospital, Milan; Department of Life Sciences (M.A.B.), University of Siena; Department NEUROFARBA (M.P.A.), University of Florence; and IRCCS Fondazione Don Carlo Gnocchi (M.P.A.), Florence, Italy.
- Correspondence
Prof. Trojano maria.trojano{at}uniba.it
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.